<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="239">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01193933</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-2009</org_study_id>
    <nct_id>NCT01193933</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexamethasone Switch in Prednisolone Resistant Adult ALL and Prolonged L-asparaginase in Non-interrupted Schedule</brief_title>
  <official_title>Multicenter Clinical Trial for Adult Ph-negative ALL Evaluating the Efficacy of Dexamethasone Switch in Case of Prednisolone Resistance and Prolonged L-asparaginase in Non-interrupted Treatment Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <authority>Russia: Ministry of Health and Social Development of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the
           efficacy of its substitution by dexamethasone if blast count is 25% and more

        2. feasibility for adults of &quot;no interruptions&quot; protocol with 8 weeks induction and 14
           weeks consolidation followed by 2-years maintenance.

        3. tolerability and efficacy in adults of the prolonged L-asparaginase application (total
           proposed dose 560.000 IU)

        4. feasibility and efficacy of autologous HSCT for T-cell ALL
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of adult ALL patients who tolerated the non-interrupted treatment</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukwmia efficacy in those subgroups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of prolonged L-asparaginase in adult patients</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukwmia of those patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Ph-negative Adult Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <description>prolonged L-asparaginase application at 10.000 IU weekly in induction, once in two weeks in 14 weeks consolidation, twice a month in maintenance (total proposed dose 560.000 IU)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph-negative precursors ALL

          -  age 15-55 years

          -  nontreated

          -  ECOG 0-3

        Exclusion Criteria:

          -  B-mature ALL

          -  Ph-positivity

          -  pretreatment

          -  ECOG 4
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeri G Savchenko, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena N Parovichnikova, Ass Prof</last_name>
    <phone>+7-495-612-43-13</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Russian Acute Lymphoblastic Leukemia Study group</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena N Parovichnikova, Ass Prof</last_name>
      <phone>+7-495-612-43-13</phone>
      <email>elenap@blood.ru</email>
    </contact>
    <investigator>
      <last_name>Andrey N Sokolov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Yu Baranova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatyana I Kaporskaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena V Kondakova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatyana V Ryltzova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey N Bondarenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>September 1, 2010</lastchanged_date>
  <firstreceived_date>August 31, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Valeri G. Savchenko, MD,PhD,Prof</name_title>
    <organization>Russian acute lymphoblastic leukemia study group</organization>
  </responsible_party>
  <keyword>adult ALL</keyword>
  <keyword>Ph-negative</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>L-asparaginase</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
</clinical_study>
